Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance...

by Gaurav Shah, Fady M. Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P. Erba, Nikolaos Papadantonakis
Published 2020-09-01

Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

by Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Published 2017-01-01

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.

by Kentaro Minagawa, Muhammad O Jamil, Mustafa Al-Obaidi, Larisa Pereboeva, Donna Salzman, Harry P Erba, Lawrence S Lamb, Ravi Bhatia, Shin Mineishi, Antonio Di Stasi
Published 2016-01-01

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

by Era L. Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R. Appelbaum, Thomas R. Chauncey, I-Ming L. Chen, Harry P. Erba, John E. Godwin, Isaac C. Jenkins, Min Fang, Mike Huynh, Kenneth J. Kopecky, Alan F. List, Jasmine Naru, Jerald P. Radich, Emily Stevens, Brooke E. Willborg, Cheryl L. Willman, Brent L. Wood, Qing Zhang, Soheil Meshinchi, Derek L. Stirewalt
Published 2020-08-01